Attila KÃ¶falvi

List of Publications by Year
in descending order

57	3,584	186265 28	189892 50
papers	citations	h-index	g-index

57	57	57	4344
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Presynaptically Located CB1 Cannabinoid Receptors Regulate GABA Release from Axon Terminals of Specific Hippocampal Interneurons. Journal of Neuroscience, 1999, 19, 4544-4558.	3.6	1,030
2	Involvement of P2X7 receptors in the regulation of neurotransmitter release in the rat hippocampus. Journal of Neurochemistry, 2002, 81, 1196-1211.	3.9	247
3	Involvement of Cannabinoid Receptors in the Regulation of Neurotransmitter Release in the Rodent Striatum: A Combined Immunochemical and Pharmacological Analysis. Journal of Neuroscience, 2005, 25, 2874-2884.	3.6	221
4	GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus. Neuroscience, 2000, 100, 797-804.	2.3	219
5	Molecular reorganization of endocannabinoid signalling in Alzheimerâ€™s disease. Brain, 2011, 134, 1041-1060.	7.6	164
6	Modification upon aging of the density of presynaptic modulation systems in the hippocampus. Neurobiology of Aging, 2009, 30, 1877-1884.	3.1	117
7	Differential glutamate-dependent and glutamate-independent adenosine A1receptor-mediated modulation of dopamine release in different striatal compartments. Journal of Neurochemistry, 2007, 101, 355-363.	3.9	104
8	Behavioral Phenotyping of Parkin-Deficient Mice: Looking for Early Preclinical Features of Parkinson's Disease. PLoS ONE, 2014, 9, e114216.	2.5	94
9	Caffeine regulates frontocorticostriatal dopamine transporter density and improves attention and cognitive deficits in an animal model of attention deficit hyperactivity disorder. European Neuropsychopharmacology, 2013, 23, 317-328.	0.7	92
10	Supersensitivity of P2X7 receptors in cerebrocortical cell cultures after inâ€ƒvitro ischemia. Journal of Neurochemistry, 2005, 95, 1421-1437.	3.9	81
11	CB1 Receptor Antagonism Increases Hippocampal Acetylcholine Release: Site and Mechanism of Action. Molecular Pharmacology, 2006, 70, 1236-1245.	2.3	78
12	Cannabis: A Treasure Trove or Pandora's Box?. Mini-Reviews in Medicinal Chemistry, 2017, 17, 1223-1291.	2.4	67
13	Cannabinoids inhibit the release of [3H]glutamate from rodent hippocampal synaptosomes via a novel CB1 receptor-independent action. European Journal of Neuroscience, 2003, 18, 1973-1978.	2.6	65
14	Cannabinoids inhibit the synaptic uptake of adenosine and dopamine in the rat and mouse striatum. European Journal of Pharmacology, 2011, 655, 38-45.	3.5	64
15	Pre-synaptic adenosine A2A receptors control cannabinoid CB1 receptor-mediated inhibition of striatal glutamatergic neurotransmission. Journal of Neurochemistry, 2011, 116, 273-280.	3.9	59
16	Glutamate-induced and NMDA receptor-mediated neurodegeneration entails P2Y1 receptor activation. Cell Death and Disease, 2018, 9, 297.	6.3	58
17	Neuronal Adenosine A2A Receptors Are Critical Mediators of Neurodegeneration Triggered by Convulsions. ENeuro, 2018, 5, ENEURO.0385-18.2018.	1.9	58
18	Caffeine Reverts Memory But Not Mood Impairment in a Depression-Prone Mouse Strain with Up-Regulated Adenosine A2A Receptor in Hippocampal Glutamate Synapses. Molecular Neurobiology, 2017, 54, 1552-1563.	4.0	55

#	ARTICLE	IF	CITATIONS
19	Control of glutamate release by complexes of adenosine and cannabinoid receptors. BMC Biology, 2020, 18, 9.	3.8	51
20	Presynaptic adenosine <scp>A_{2A}</scp> receptors dampen cannabinoid <scp>CB</scp>₁ receptorâ€mediated inhibition of corticostriatal glutamatergic transmission. British Journal of Pharmacology, 2015, 172, 1074-1086.	5.4	45
21	Adenosine A_{2b} receptors control A₁ receptorâ€mediated inhibition of synaptic transmission in the mouse hippocampus. European Journal of Neuroscience, 2015, 41, 878-888.	2.6	43
22	Stimulation of brain glucose uptake by cannabinoid CB2 receptors and its therapeutic potential in Alzheimer's disease. Neuropharmacology, 2016, 110, 519-529.	4.1	43
23	Lack of evidence for functional TRPV1 vanilloid receptors in rat hippocampal nerve terminals. Neuroscience Letters, 2006, 403, 151-156.	2.1	39
24	P2X Receptor Activation Elicits Transporter-Mediated Noradrenaline Release from Rat Hippocampal Slices. Journal of Pharmacology and Experimental Therapeutics, 2004, 310, 973-980.	2.5	38
25	Increase of cannabinoid CB1 receptor density in the hippocampus of streptozotocin-induced diabetic rats. Experimental Neurology, 2007, 204, 479-484.	4.1	34
26	Anandamide and NADA bi-directionally modulate presynaptic Ca2+ levels and transmitter release in the hippocampus. British Journal of Pharmacology, 2007, 151, 551-563.	5.4	34
27	Presynaptic CB1 cannabinoid receptors control frontocortical serotonin and glutamate release â€“ Species differences. Neurochemistry International, 2012, 61, 219-226.	3.8	33
28	Functional interaction between preâ€synaptic <scp>Î±6Î²2</scp>â€containing nicotinic and adenosine <scp>A_{2A}</scp> receptors in the control of dopamine release in the rat striatum. British Journal of Pharmacology, 2013, 169, 1600-1611.	5.4	29
29	Ketone bodies effectively compete with glucose for neuronal acetylâ€CoA generation in rat hippocampal slices. NMR in Biomedicine, 2015, 28, 1111-1116.	2.8	28
30	Diabetes induces early transient changes in the content of vesicular transporters and no major effects in neurotransmitter release in hippocampus and retina. Brain Research, 2011, 1383, 257-269.	2.2	27
31	CB1 receptor activation inhibits neuronal and astrocytic intermediary metabolism in the rat hippocampus. Neurochemistry International, 2012, 60, 1-8.	3.8	27
32	Adenosine A2B receptor activation stimulates glucose uptake in the mouse forebrain. Purinergic Signalling, 2015, 11, 561-569.	2.2	26
33	Memory deficits induced by chronic cannabinoid exposure are prevented by adenosine A2AR receptor antagonism. Neuropharmacology, 2019, 155, 10-21.	4.1	21
34	Functional Identification of Cell Phenotypes Differentiating from Mice Retinal Neurospheres Using Single Cell Calcium Imaging. Cellular and Molecular Neurobiology, 2011, 31, 835-846.	3.3	19
35	N-acyldopamines control striatal input terminals via novel ligand-gated cation channels. Neuropharmacology, 2009, 56, 676-683.	4.1	17
36	Presynaptic Î±2-adrenoceptors control the inhibitory action of presynaptic CB1 cannabinoid receptors on prefrontocortical norepinephrine release in the rat. Neuropharmacology, 2012, 63, 784-797.	4.1	17

#	ARTICLE	IF	CITATIONS
37	Adenosine A2A Receptors in the Rat Prelimbic Medial Prefrontal Cortex Control Delay-Based Cost-Benefit Decision Making. Frontiers in Molecular Neuroscience, 2018, 11, 475.	2.9	16
38	Presynaptic TRPV1 vanilloid receptor function is age- but not CB1 cannabinoid receptor-dependent in the rodent forebrain. Brain Research Bulletin, 2013, 97, 126-135.	3.0	14
39	Excessive release of [3H]noradrenaline by veratridine and ischemia in spinal cord. Neurochemistry International, 2001, 39, 59-63.	3.8	13
40	Hierarchical glucocorticoid-endocannabinoid interplay regulates the activation of the nucleus accumbens by insulin. Brain Research Bulletin, 2016, 124, 222-230.	3.0	12
41	Methamphetamine Induces Anhedonicâ€Like Behavior and Impairs Frontal Cortical Energetics in Mice. CNS Neuroscience and Therapeutics, 2017, 23, 119-126.	3.9	12
42	Brain Iron Deficiency Changes the Stoichiometry of Adenosine Receptor Subtypes in Cortico-Striatal Terminals: Implications for Restless Legs Syndrome. Molecules, 2022, 27, 1489.	3.8	11
43	Lack of presynaptic interaction between glucocorticoid and CB1 cannabinoid receptors in GABA- and glutamatergic terminals in the frontal cortex of laboratory rodents. Neurochemistry International, 2015, 90, 72-84.	3.8	9
44	Cannabinoids and the Brain. , 2008, , .		8
45	Distinct mechanisms underlying alpha1-adrenoceptor and P2x purinoceptor operated ATP release and contraction in the guinea-pig vas deferens. Neurochemical Research, 2001, 26, 951-957.	3.3	7
46	Boosting brain glucose metabolism to fight neurodegeneration?. Oncotarget, 2017, 8, 14273-14274.	1.8	7
47	Impaired hippocampal glucoregulation in the cannabinoid CB1 receptor knockout mice as revealed by an optimized in vitro experimental approach. Journal of Neuroscience Methods, 2012, 204, 366-373.	2.5	6
48	Alternative Interacting Sites and Novel Receptors for Cannabinoid Ligands. , 2008, , 131-160.		5
49	Diabetes and Cannabinoid CB1 receptor deficiency promote similar early onset aging-like changes in the skin. Experimental Gerontology, 2021, 154, 111528.	2.8	5
50	Chronic insulinopenia/hyperglycemia decreases cannabinoid CB1 receptor density and impairs glucose uptake in the mouse forebrain. Brain Research Bulletin, 2019, 147, 101-109.	3.0	4
51	An optimized spectrophotometric assay reveals increased activity of enzymes involved in 2â€arachidonoyl glycerol turnover in the cerebral cortex of a rat model of Alzheimerâ€™s disease. European Journal of Neuroscience, 2022, 55, 1051-1062.	2.6	3
52	Transient gain of function of cannabinoid CB1 receptors in the control of frontocortical glucose consumption in a rat model of Type-1 diabetes. Brain Research Bulletin, 2020, 161, 106-115.	3.0	3
53	The Endocannabinoid System is a Major Player in Schizophrenia. , 2008, , 485-528.		3
54	An Historical Introduction to the Endocannabinoid and Endovanilloid Systems. , 2008, , 3-13.		1

#	ARTICLE	IF	CITATIONS
55	Endocannabinoids in Energy Homeostasis and Metabolic Disorders. , 2008, , 277-316.		1
56	The Yin and Yang of Adenosine Receptors: A Piquant Story. Journal of Caffeine and Adenosine Research, 2020, 10, 42-44.	0.6	0
57	Synthetic cannabinoids inhibit the dopamine transporter whereby increasing stimulated presynaptic net dopamine release in the rat striatum. Frontiers in Neuroscience, 0, 3, .	2.8	0